Greenleaf Trust Has $796,000 Stake in Sanofi (NASDAQ:SNY)

Greenleaf Trust boosted its position in shares of Sanofi (NASDAQ:SNY) by 8.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,814 shares of the company’s stock after acquiring an additional 1,025 shares during the period. Greenleaf Trust’s holdings in Sanofi were worth $796,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. POM Investment Strategies LLC acquired a new position in shares of Sanofi during the second quarter valued at about $25,000. Register Financial Advisors LLC acquired a new position in shares of Sanofi during the first quarter valued at about $29,000. Larson Financial Group LLC raised its position in shares of Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the last quarter. Northwest Investment Counselors LLC acquired a new position in shares of Sanofi during the third quarter valued at about $29,000. Finally, Palisade Asset Management LLC acquired a new position in shares of Sanofi during the first quarter valued at about $31,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ SNY opened at $52.05 on Friday. The stock has a market cap of $132.08 billion, a P/E ratio of 28.29, a PEG ratio of 1.40 and a beta of 0.60. The company’s 50-day simple moving average is $56.12 and its 200 day simple moving average is $51.67. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.95 earnings per share. As a group, research analysts forecast that Sanofi will post 4.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research analyst reports. Argus upped their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.